SG188543A1 - Use of myeloid cell biomarkers for the diagnosis of cancer - Google Patents
Use of myeloid cell biomarkers for the diagnosis of cancer Download PDFInfo
- Publication number
- SG188543A1 SG188543A1 SG2013018973A SG2013018973A SG188543A1 SG 188543 A1 SG188543 A1 SG 188543A1 SG 2013018973 A SG2013018973 A SG 2013018973A SG 2013018973 A SG2013018973 A SG 2013018973A SG 188543 A1 SG188543 A1 SG 188543A1
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- patient
- treatment
- mdsc
- treated
- Prior art date
Links
Classifications
-
- G01N33/575—
-
- G01N33/57535—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G01N33/5751—
-
- G01N33/57525—
-
- G01N33/5753—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478410P | 2010-09-21 | 2010-09-21 | |
| GBGB1015765.9A GB201015765D0 (en) | 2010-09-21 | 2010-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| PCT/EP2011/066397 WO2012038463A2 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG188543A1 true SG188543A1 (en) | 2013-04-30 |
Family
ID=43065538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013018973A SG188543A1 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| SG10201510470WA SG10201510470WA (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201510470WA SG10201510470WA (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9671404B2 (enExample) |
| EP (1) | EP2619585B1 (enExample) |
| JP (1) | JP5970459B2 (enExample) |
| KR (1) | KR20130137635A (enExample) |
| CN (1) | CN103180739B (enExample) |
| CA (1) | CA2811070A1 (enExample) |
| EA (1) | EA201390413A1 (enExample) |
| GB (1) | GB201015765D0 (enExample) |
| SG (2) | SG188543A1 (enExample) |
| WO (1) | WO2012038463A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013169913A1 (en) * | 2012-05-08 | 2013-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Predictors of patient response to interferon-a therapy |
| US20160030558A1 (en) * | 2013-03-13 | 2016-02-04 | Health Research, Inc. | Enhancement of vaccines |
| CN103743907B (zh) * | 2013-07-24 | 2015-04-15 | 北京大学人民医院 | 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法 |
| WO2015048748A1 (en) * | 2013-09-30 | 2015-04-02 | Board Of Regents, The University Of Texas System | Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use |
| CN103626846B (zh) * | 2013-11-08 | 2016-06-01 | 上海交通大学 | 与MDSCs特异性结合的配体多肽及药物输送系统 |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| WO2016210241A1 (en) * | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| MX2018002640A (es) * | 2015-09-02 | 2018-06-20 | Syndax Pharmaceuticals Inc | Seleccion de pacientes para la terapia de combinacion. |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| EP4438626A3 (en) | 2016-04-14 | 2024-12-04 | OSE Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN107102127B (zh) * | 2017-04-07 | 2019-08-06 | 东北师范大学 | 一种人体外周血中单核样髓源抑制细胞的检测方法 |
| AU2018269039B2 (en) | 2017-05-19 | 2025-05-15 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| WO2018221820A1 (ko) * | 2017-06-02 | 2018-12-06 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
| CA3091468A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
| WO2019217484A1 (en) | 2018-05-07 | 2019-11-14 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN110501483B (zh) * | 2019-07-25 | 2020-12-29 | 同济大学 | 一种中草药活性的检测方法 |
| TR202003833A1 (tr) | 2020-03-12 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇ |
| EP4347653A1 (en) | 2021-06-04 | 2024-04-10 | Boehringer Ingelheim International GmbH | Anti-sirp-alpha antibodies |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
| CN117030580B (zh) * | 2023-09-15 | 2024-07-16 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | LDNs在坏死性小肠结肠炎诊断中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US20040136973A1 (en) * | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
| US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
-
2010
- 2010-09-21 GB GBGB1015765.9A patent/GB201015765D0/en not_active Ceased
-
2011
- 2011-09-21 SG SG2013018973A patent/SG188543A1/en unknown
- 2011-09-21 SG SG10201510470WA patent/SG10201510470WA/en unknown
- 2011-09-21 KR KR1020137010009A patent/KR20130137635A/ko not_active Withdrawn
- 2011-09-21 CA CA2811070A patent/CA2811070A1/en not_active Abandoned
- 2011-09-21 CN CN201180045200.3A patent/CN103180739B/zh not_active Expired - Fee Related
- 2011-09-21 JP JP2013528723A patent/JP5970459B2/ja not_active Expired - Fee Related
- 2011-09-21 US US13/239,011 patent/US9671404B2/en not_active Expired - Fee Related
- 2011-09-21 EA EA201390413A patent/EA201390413A1/ru unknown
- 2011-09-21 WO PCT/EP2011/066397 patent/WO2012038463A2/en not_active Ceased
- 2011-09-21 EP EP11758209.8A patent/EP2619585B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103180739B (zh) | 2016-08-03 |
| CN103180739A (zh) | 2013-06-26 |
| JP5970459B2 (ja) | 2016-08-17 |
| JP2013539857A (ja) | 2013-10-28 |
| US9671404B2 (en) | 2017-06-06 |
| WO2012038463A3 (en) | 2012-07-26 |
| EP2619585A2 (en) | 2013-07-31 |
| GB201015765D0 (en) | 2010-10-27 |
| KR20130137635A (ko) | 2013-12-17 |
| SG10201510470WA (en) | 2016-01-28 |
| WO2012038463A2 (en) | 2012-03-29 |
| EA201390413A1 (ru) | 2013-07-30 |
| US20120070461A1 (en) | 2012-03-22 |
| CA2811070A1 (en) | 2012-03-29 |
| EP2619585B1 (en) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9671404B2 (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
| Eugène et al. | The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression | |
| Wu et al. | Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia | |
| CN103384827B (zh) | 用于预测癌症免疫治疗效果的生物标记 | |
| Kim et al. | Dynamic changes in circulating PD-1+ CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | |
| EP3022561B1 (en) | Method for the prognosis of survival time of a patient suffering from a solid cancer | |
| US20210017607A1 (en) | Methods of Predicting Responsiveness to Cancer Therapies | |
| Akazawa et al. | Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes | |
| Yu et al. | CCR9-CCL25 mediated plasmacytoid dendritic cell homing and contributed the immunosuppressive microenvironment in gastric cancer | |
| JP2024151758A (ja) | 肝臓癌を治療する方法、治療に対する応答を予測する方法、及び肝臓癌の治療中の有害作用を予測する方法 | |
| Schmitt et al. | The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses | |
| JP7216420B2 (ja) | がん治療効果の検査方法及び免疫応答誘導用組成物 | |
| Andersson et al. | Prognostic significance of specific anti‐WT 1 IgG antibody level in plasma in patients with ovarian carcinoma | |
| HK1183096A (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
| HK1183096B (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
| Copier et al. | Biomarkers for the development of cancer vaccines: current status | |
| WO2023218399A1 (en) | Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies | |
| Camcı et al. | Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer | |
| Li et al. | Longitudinal high-dimensional analysis identifies biomarkers of response to anti-PD-1 immunotherapy | |
| Sesma et al. | Peripheral blood TCRβ repertoire, IL15, IL2 and soluble ligands for NKG2D activating receptor predict efficacy of ICI in lung cancer | |
| Xie et al. | Diagnostic value of the circulating tumor cells and circulating tumor-derived endothelial cells detection for non-small cell lung cancer | |
| Kostine | Defining the immune microenvironment in sarcoma: could immunotherapy be part of the treatment strategy in sarcoma patients? | |
| CN120983632A (zh) | 一种靶向蛋白adgre2的急性髓系白血病治疗药物和应用 | |
| Tarhoni | Characterization of Biomarkers Associated with Response to Programmed Cell Death Protein-1/Programmed Cell Death Ligand-1 Inhibition in Patients with Advanced Stage Non-small Cell Lung Cancer | |
| Zhang et al. | 1344 Warthin’s Tumor: A Study of 73 Cases with Emphasis on Association with Other Malignancies |